$ISCO
International Stem Cell CORP

2023 Q3 Form 10-Q Financial Statement

#000095017023041762 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $1.973M $1.841M
YoY Change 15.85% -9.18%
Cost Of Revenue $781.0K $713.0K
YoY Change 13.19% -0.7%
Gross Profit $1.192M $1.128M
YoY Change 17.67% -13.83%
Gross Profit Margin 60.42% 61.27%
Selling, General & Admin $1.134M $1.227M
YoY Change -2.74% 2.68%
% of Gross Profit 95.13% 108.78%
Research & Development $155.0K $45.00K
YoY Change 5.44% -45.78%
% of Gross Profit 13.0% 3.99%
Depreciation & Amortization $47.00K $48.00K
YoY Change -14.55% -12.73%
% of Gross Profit 3.94% 4.26%
Operating Expenses $1.289M $1.272M
YoY Change -1.83% -0.47%
Operating Profit -$97.00K -$144.0K
YoY Change -67.67% -564.52%
Interest Expense $34.00K $35.00K
YoY Change -197.14% -206.06%
% of Operating Profit
Other Income/Expense, Net -$34.00K $636.0K
YoY Change -20.93% -2027.27%
Pretax Income -$131.0K $492.0K
YoY Change -61.81% -24700.0%
Income Tax
% Of Pretax Income
Net Earnings -$131.0K $492.0K
YoY Change -61.81% -24700.0%
Net Earnings / Revenue -6.64% 26.72%
Basic Earnings Per Share -$0.02 $0.03
Diluted Earnings Per Share -$0.02 $0.03
COMMON SHARES
Basic Shares Outstanding 8.004M 8.004M
Diluted Shares Outstanding 8.004M 8.004M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.430M $1.382M
YoY Change 114.71% 135.84%
Cash & Equivalents $1.430M $1.382M
Short-Term Investments
Other Short-Term Assets $16.00K $32.00K
YoY Change -69.81% -49.21%
Inventory $1.317M $1.296M
Prepaid Expenses $152.0K $213.0K
Receivables $644.0K $662.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.658M $3.684M
YoY Change 35.48% 23.05%
LONG-TERM ASSETS
Property, Plant & Equipment $243.0K $256.0K
YoY Change -12.9% -18.21%
Goodwill
YoY Change
Intangibles $892.0K $837.0K
YoY Change -0.45% -8.72%
Long-Term Investments
YoY Change
Other Assets $320.0K $363.0K
YoY Change -20.6% -7.4%
Total Long-Term Assets $1.983M $2.102M
YoY Change -15.33% -13.21%
TOTAL ASSETS
Total Short-Term Assets $3.658M $3.684M
Total Long-Term Assets $1.983M $2.102M
Total Assets $5.641M $5.786M
YoY Change 11.88% 6.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $303.0K $331.0K
YoY Change -19.84% -30.61%
Accrued Expenses $442.0K $521.0K
YoY Change -6.95% 3.99%
Deferred Revenue
YoY Change
Short-Term Debt $3.424M $3.390M
YoY Change 4.04% 4.05%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.682M $4.744M
YoY Change 1.5% 1.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $518.0K $588.0K
YoY Change -33.67% -30.0%
Total Long-Term Liabilities $518.0K $588.0K
YoY Change -33.67% -30.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.682M $4.744M
Total Long-Term Liabilities $518.0K $588.0K
Total Liabilities $5.200M $5.332M
YoY Change -3.6% -3.65%
SHAREHOLDERS EQUITY
Retained Earnings -$110.0M -$109.9M
YoY Change -0.36% -0.09%
Common Stock $8.000K $8.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.859M -$3.846M
YoY Change
Total Liabilities & Shareholders Equity $5.641M $5.786M
YoY Change 11.88% 6.83%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$131.0K $492.0K
YoY Change -61.81% -24700.0%
Depreciation, Depletion And Amortization $47.00K $48.00K
YoY Change -14.55% -12.73%
Cash From Operating Activities $62.00K $490.0K
YoY Change -26.19% 155.21%
INVESTING ACTIVITIES
Capital Expenditures $14.00K $51.00K
YoY Change -450.0% -1375.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$14.00K -$51.00K
YoY Change 250.0% 1175.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities 62.00K 490.0K
Cash From Investing Activities -14.00K -51.00K
Cash From Financing Activities 0.000 0.000
Net Change In Cash 48.00K 439.0K
YoY Change -40.0% 133.51%
FREE CASH FLOW
Cash From Operating Activities $62.00K $490.0K
Capital Expenditures $14.00K $51.00K
Free Cash Flow $48.00K $439.0K
YoY Change -45.45% 123.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001355790
CY2023Q2 us-gaap Notes Payable Current Related And Nonrelated Party Status Extensible Enumeration
NotesPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Notes Payable Current Related And Nonrelated Party Status Extensible Enumeration
NotesPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2022Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-51891
dei Entity Registrant Name
EntityRegistrantName
INTERNATIONAL STEM CELL CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4494098
dei Entity Address Address Line1
EntityAddressAddressLine1
9745 Businesspark Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92131
dei City Area Code
CityAreaCode
760
dei Local Phone Number
LocalPhoneNumber
940-6383
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8004389
CY2023Q2 us-gaap Cash
Cash
1382000
CY2022Q4 us-gaap Cash
Cash
742000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
662000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
747000
CY2023Q2 us-gaap Inventory Net
InventoryNet
1296000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1384000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
344000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
90000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
3684000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2963000
CY2023Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
326000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
286000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
256000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
837000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
878000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
646000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
727000
CY2023Q2 isco Deposits And Other Assets
DepositsAndOtherAssets
37000
CY2022Q4 isco Deposits And Other Assets
DepositsAndOtherAssets
33000
CY2023Q2 us-gaap Assets
Assets
5786000
CY2022Q4 us-gaap Assets
Assets
5135000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
331000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
322000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
521000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
508000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
252000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
230000
CY2023Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2022Q4 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
3390000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3325000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4744000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4635000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
588000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
720000
CY2023Q2 us-gaap Liabilities
Liabilities
5332000
CY2022Q4 us-gaap Liabilities
Liabilities
5355000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8004389
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8004389
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8004389
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8004389
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
106028000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105812000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109887000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110345000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3846000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4520000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5786000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5135000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1841000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2027000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3927000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4047000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
713000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
718000
us-gaap Cost Of Revenue
CostOfRevenue
1537000
us-gaap Cost Of Revenue
CostOfRevenue
1443000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
918000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
872000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1718000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1704000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
309000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
323000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
624000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
624000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
190000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
220000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
1985000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
1996000
us-gaap Costs And Expenses
CostsAndExpenses
4069000
us-gaap Costs And Expenses
CostsAndExpenses
3991000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-144000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
31000
us-gaap Operating Income Loss
OperatingIncomeLoss
-142000
us-gaap Operating Income Loss
OperatingIncomeLoss
56000
CY2023Q2 us-gaap Interest Expense
InterestExpense
35000
CY2022Q2 us-gaap Interest Expense
InterestExpense
33000
us-gaap Interest Expense
InterestExpense
71000
us-gaap Interest Expense
InterestExpense
67000
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
671000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
671000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
636000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
600000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-67000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
492000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2000
us-gaap Net Income Loss
NetIncomeLoss
458000
us-gaap Net Income Loss
NetIncomeLoss
-11000
CY2023Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
233000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
217000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
259000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
241000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4520000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
108000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4446000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
108000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
492000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3846000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-4588000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
91000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4506000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
90000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4418000
us-gaap Profit Loss
ProfitLoss
458000
us-gaap Profit Loss
ProfitLoss
-11000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
99000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
111000
isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
81000
isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
68000
us-gaap Share Based Compensation
ShareBasedCompensation
216000
us-gaap Share Based Compensation
ShareBasedCompensation
181000
isco Interest Expense On Related Party Note Payable
InterestExpenseOnRelatedPartyNotePayable
65000
isco Interest Expense On Related Party Note Payable
InterestExpenseOnRelatedPartyNotePayable
67000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-85000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-181000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-48000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
164000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
254000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
249000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
4000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-5000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-36000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
97000
isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-110000
isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-81000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
706000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
169000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
250000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
250000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
640000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
415000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
742000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1382000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
586000
us-gaap Interest Paid Net
InterestPaidNet
5000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000
isco Patent License Costs Included In Accounts Payable
PatentLicenseCostsIncludedInAccountsPayable
5000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, and the fair value of stock option grants using the Black-Scholes option valuation model. By their nature, estimates are subject to an inherent degree of uncertainty and actual results could differ from these estimates.</span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical market (LCT) and anti-aging market (LSC). The anti-aging market sells products solely through the ecommerce channel. The biomedical market sells primary human cell research products with two product categories, cells and media, which are sold both domestically and internationally. The biomedical market also offers performance of quality control (QC) testing services. No revenue from services was earned during the three and six months ended June 30, 2023 and 2022.
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2023Q2 isco Number Of Products Categories
NumberOfProductsCategories
2
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
662000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
747000
CY2023Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
isco Reduction In Research And Development Expenses
ReductionInResearchAndDevelopmentExpenses
99000
isco Reduction In Research And Development Expenses
ReductionInResearchAndDevelopmentExpenses
80000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
492000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2000
us-gaap Net Income Loss
NetIncomeLoss
458000
us-gaap Net Income Loss
NetIncomeLoss
-11000
CY2023Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
233000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
217000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
259000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
259000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
241000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
241000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.03
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.03
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.03
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.03
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14536237
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12939614
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14309231
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12939614
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Concentrations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three months ended June 30, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> customer accounted for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of consolidated revenues, respectively. For the six months ended June 30, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> customer accounted for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of consolidated revenues in both periods. As of both June 30, 2023 and December 31, 2022, the same customer accounted for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accounts receivable, net, respectively. No other single customer accounted for more than 10% of revenues for the periods then ended for any segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
612000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
615000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
535000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
498000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1142000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1194000
CY2023Q2 us-gaap Inventory Gross
InventoryGross
2289000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
2307000
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
667000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
637000
CY2023Q2 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1622000
CY2022Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1670000
CY2023Q2 us-gaap Inventory Net
InventoryNet
1296000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1384000
CY2023Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
326000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
286000
CY2023Q2 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1622000
CY2022Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1670000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
213000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
64000
CY2023Q2 isco Australian Research And Development Tax Credit
AustralianResearchAndDevelopmentTaxCredit
99000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
32000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
26000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
344000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
90000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2529000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2467000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2273000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2219000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
256000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
27000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
35000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
58000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
72000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1286000
CY2022Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1286000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
524000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
483000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
762000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
803000
CY2023Q2 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2022Q4 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
837000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
878000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
20000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
41000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
39000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2023Q2 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
1
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0399
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0286
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.895
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9029
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M15D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.33
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
108000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
90000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
216000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
181000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
657000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M21D
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16754269
CY2021Q4 isco Lease Costs Incurred Percentage
LeaseCostsIncurredPercentage
0.40
isco Number Of Operating Leases
NumberOfOperatingLeases
3
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
11000
CY2021Q4 isco Percentage Of Increase Rent Per Annum Over Lease Term
PercentageOfIncreaseRentPerAnnumOverLeaseTerm
0.035
CY2021Q4 isco Percentage Of Base Rent Abated
PercentageOfBaseRentAbated
0.50
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
71000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
72000
us-gaap Operating Lease Cost
OperatingLeaseCost
142000
us-gaap Operating Lease Cost
OperatingLeaseCost
145000
CY2023Q2 isco Finance Leases
FinanceLeases
0
CY2022Q4 isco Finance Leases
FinanceLeases
0
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
169000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
350000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
360000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
119000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
998000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
158000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
840000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
252000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
588000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
isco Number Of Business Units
NumberOfBusinessUnits
2
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1841000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2027000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3927000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4047000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
1985000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
1996000
us-gaap Costs And Expenses
CostsAndExpenses
4069000
us-gaap Costs And Expenses
CostsAndExpenses
3991000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-144000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
31000
us-gaap Operating Income Loss
OperatingIncomeLoss
-142000
us-gaap Operating Income Loss
OperatingIncomeLoss
56000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
636000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
600000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-67000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
492000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2000
us-gaap Net Income Loss
NetIncomeLoss
458000
us-gaap Net Income Loss
NetIncomeLoss
-11000

Files In Submission

Name View Source Status
0000950170-23-041762-index-headers.html Edgar Link pending
0000950170-23-041762-index.html Edgar Link pending
0000950170-23-041762.txt Edgar Link pending
0000950170-23-041762-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
isco-20230630.htm Edgar Link pending
isco-20230630.xsd Edgar Link pending
isco-ex31_1.htm Edgar Link pending
isco-ex31_2.htm Edgar Link pending
isco-ex32_1.htm Edgar Link pending
isco-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
isco-20230630_pre.xml Edgar Link unprocessable
isco-20230630_lab.xml Edgar Link unprocessable
isco-20230630_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
isco-20230630_def.xml Edgar Link unprocessable
isco-20230630_cal.xml Edgar Link unprocessable